SAB Biotherapeutics Novel DiversitAb Platform Proven To Develop Anti-idiotype Antibodies To Help Treat Autoimmune Diseases
SAB Biotherapeutics (NASDAQ:SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for